This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Synergy Pharmaceuticals Files IND For SP-333, A Developmental Drug For Gastrointestinal Diseases

NEW YORK, Sept. 12, 2012 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that an Investigational New Drug (IND) application was submitted on September 7, 2012 for clinical evaluation of SP-333 to treat inflammatory bowel disease (IBD). SP-333 is a second-generation guanylate cyclase-C (GC-C) agonist with the potential to treat GI disorders and diseases.

"SP-333, to our knowledge, represents the most potent and stable uroguanylin analog ever developed," stated Dr. Gary S. Jacob, President and CEO of Synergy Pharmaceuticals. "The submission of the IND on SP-333 is a major milestone for the company, as it broadens our clinical portfolio of GC-C agonists for treatment of GI disorders and diseases."

"The science behind SP-333 marks a new approach to the treatment of GI inflammatory diseases," said Dr. Kunwar Shailubhai, Chief Scientific Officer of Synergy Pharmaceuticals. "We are excited with SP-333's impressive anti-inflammatory activity. In studies with experimental models of colitis in mice, SP-333 at an oral dose as low as 0.05 mg/kg body weight demonstrated superior anti-inflammatory activity compared to 5-aminosalicylic acid (5-ASA) given at a dose of 100 mg/kg."

About SP-333

SP-333 is a synthetic analog of uroguanylin, a natriuretic hormone which is normally produced in the body's intestinal tract. Deficiency of uroguanylin is likely to be one of the primary reasons associated with formation of polyps as well as debilitating and difficult-to-treat GI inflammatory disorders such as ulcerative colitis and Crohn's disease. Orally-administered SP-333 binds to and activates guanylate cyclase C (GC-C) expressed on epithelial cells lining the GI mucosa, resulting in stimulation of cyclic GMP in target tissues.  SP-333 has been found to be highly stable against proteolysis in simulated intestinal fluid for up to 24 hours.  Its enhanced stability makes this peptide an extremely potent GC-C agonist in animal studies in mice and monkeys, promoting bowel movement in monkeys, and ameliorating GI inflammation in mice, respectively.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
SYM TRADE IT LAST %CHG

Markets

DOW 18,285.74 +0.34 0.00%
S&P 500 2,130.82 +4.97 0.23%
NASDAQ 5,090.7940 +19.0510 0.38%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs